4.69
-0.18(-3.70%)
Currency In USD
Address
One Corporate Drive
South San Francisco, CA 94080
United States of America
Phone
800 466 6059
Website
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
October 16, 2020
| Name | Title | Pay | Year Born |
| Dr. Lawrence M. Blatt MBA, Ph.D. | Chief Executive Officer, President & Chairman of the Board | 1.01M | 1962 |
| Dr. Julian A. Symons DPHIL | Executive Vice President & Chief Scientific Officer | 677,467 | 1962 |
| Dr. Tse-I Lin Ph.D. | Senior Vice President of Early Compound Development & Belgian Site Head | 0 | N/A |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President & Chief Development Officer | 0 | 1967 |
| Dr. David B. Smith Ph.D. | Executive Vice President & Head of Chemical Operations | 0 | N/A |
| Ms. Kristina Engeseth M.B.A. | Senior Vice President and Head of People & Culture | 0 | N/A |
| Dr. Hardean E. Achneck M.D. | Executive Vice President & Chief Medical Officer | 0 | 1977 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
